Kyuwan Lee1, Debu Tripathy2, Wendy Demark-Wahnefried3, Kerry S Courneya4, Nathalie Sami1, Leslie Bernstein5, Darcy Spicer6, Thomas A Buchanan7, Joanne E Mortimer8, Christina M Dieli-Conwright1,6. 1. Division of Biokinesiology and Physical Therapy, University of Southern California, Los Angeles. 2. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston. 3. Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham. 4. Faculty of Kinesiology, Sport, and Recreation, University of Alberta, Edmonton, Alberta, Canada. 5. Division of Biomarkers of Early Detection and Prevention, Beckman Research Institute, City of Hope National Medical Center, Duarte, California. 6. Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles. 7. Division of Endocrinology and Diabetes, Keck School of Medicine, University of Southern California, Los Angeles. 8. Division of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Duarte, California.
Abstract
IMPORTANCE: The Framingham Risk Score (FRS) is a valid method for predicting the 10-year risk of developing cardiovascular disease. Higher FRS is reported in patients with early-stage breast cancer who are overweight than in healthy, age-matched women, but whether exercise reduces FRS in this patient population is unclear. OBJECTIVE: To examine the effects of a 16-week aerobic and resistance exercise intervention on the FRS in women with early-stage breast cancer and with overweight condition or obesity. DESIGN, SETTING, AND PARTICIPANTS: This single-center, prospective randomized clinical trial included 100 women with stage I to III breast cancer who were sedentary, with overweight condition or obesity (body mass index of ≥25.0 or body fat of ≥30%), and completed cancer treatment within 6 months prior to enrollment. Participants were randomized to either the usual care or exercise group. Differences in mean changes for outcomes were evaluated using mixed-model repeated-measures analyses. Data were collected from August 1, 2012, through July 1, 2017. Data analysis, which followed the intention-to-treat approach, was performed from May 24 to October 2, 2018. INTERVENTIONS: The exercise group underwent supervised aerobic and resistance exercise sessions thrice weekly for 16 weeks. MAIN OUTCOMES AND MEASURES: The FRS was calculated for each participant using preset points for each of the 6 FRS categories: age, systolic blood pressure, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, diabetes presence, and smoking status. RESULTS: In total, 100 women were randomized to either the exercise group (n = 50) or usual care group (n = 50). Of these women, 55 (55%) were of Hispanic white race/ethnicity and the mean (SD) age was 53.5 (10.4) years. The mean (SD) total FRS scores postintervention were 2.0 (1.5) in the exercise group and 13.0 (3.0) in the usual care group. The postintervention FRS was significantly reduced in the exercise group compared with the usual care group (mean, -9.5; 95% CI, -13.0 to -6.0), which corresponds to an 11% (95% CI, -15.0 to -5.0) decrease on the FRS-predicted 10-year risk of developing cardiovascular disease. CONCLUSIONS AND RELEVANCE: A 16-week supervised aerobic and resistance exercise intervention appeared to reduce the FRS-predicted 10-year risk of cardiovascular disease in women with early-stage breast cancer with overweight condition or obesity. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01140282.
IMPORTANCE: The Framingham Risk Score (FRS) is a valid method for predicting the 10-year risk of developing cardiovascular disease. Higher FRS is reported in patients with early-stage breast cancer who are overweight than in healthy, age-matched women, but whether exercise reduces FRS in this patient population is unclear. OBJECTIVE: To examine the effects of a 16-week aerobic and resistance exercise intervention on the FRS in women with early-stage breast cancer and with overweight condition or obesity. DESIGN, SETTING, AND PARTICIPANTS: This single-center, prospective randomized clinical trial included 100 women with stage I to III breast cancer who were sedentary, with overweight condition or obesity (body mass index of ≥25.0 or body fat of ≥30%), and completed cancer treatment within 6 months prior to enrollment. Participants were randomized to either the usual care or exercise group. Differences in mean changes for outcomes were evaluated using mixed-model repeated-measures analyses. Data were collected from August 1, 2012, through July 1, 2017. Data analysis, which followed the intention-to-treat approach, was performed from May 24 to October 2, 2018. INTERVENTIONS: The exercise group underwent supervised aerobic and resistance exercise sessions thrice weekly for 16 weeks. MAIN OUTCOMES AND MEASURES: The FRS was calculated for each participant using preset points for each of the 6 FRS categories: age, systolic blood pressure, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, diabetes presence, and smoking status. RESULTS: In total, 100 women were randomized to either the exercise group (n = 50) or usual care group (n = 50). Of these women, 55 (55%) were of Hispanic white race/ethnicity and the mean (SD) age was 53.5 (10.4) years. The mean (SD) total FRS scores postintervention were 2.0 (1.5) in the exercise group and 13.0 (3.0) in the usual care group. The postintervention FRS was significantly reduced in the exercise group compared with the usual care group (mean, -9.5; 95% CI, -13.0 to -6.0), which corresponds to an 11% (95% CI, -15.0 to -5.0) decrease on the FRS-predicted 10-year risk of developing cardiovascular disease. CONCLUSIONS AND RELEVANCE: A 16-week supervised aerobic and resistance exercise intervention appeared to reduce the FRS-predicted 10-year risk of cardiovascular disease in women with early-stage breast cancer with overweight condition or obesity. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01140282.
Authors: Patrick T Bradshaw; June Stevens; Nikhil Khankari; Susan L Teitelbaum; Alfred I Neugut; Marilie D Gammon Journal: Epidemiology Date: 2016-01 Impact factor: 4.822
Authors: Christina M Dieli-Conwright; Kerry S Courneya; Wendy Demark-Wahnefried; Nathalie Sami; Kyuwan Lee; Thomas A Buchanan; Darcy V Spicer; Debu Tripathy; Leslie Bernstein; Joanne E Mortimer Journal: J Clin Oncol Date: 2018-01-22 Impact factor: 44.544
Authors: Christina M Dieli-Conwright; Joanne E Mortimer; E Todd Schroeder; Kerry Courneya; Wendy Demark-Wahnefried; Thomas A Buchanan; Debu Tripathy; Leslie Bernstein Journal: BMC Cancer Date: 2014-04-03 Impact factor: 4.430
Authors: Vanessa B Sheppard; Chiranjeev Dash; Sarah Nomura; Arnethea L Sutton; Robert Lee Franco; Alexander Lucas; Masey Ross; Lucile Adams-Campbell Journal: Cancer Date: 2020-07-02 Impact factor: 6.860
Authors: Olivier Morin; Martin Vallières; Steve Braunstein; Jorge Barrios Ginart; Taman Upadhaya; Henry C Woodruff; Alex Zwanenburg; Avishek Chatterjee; Javier E Villanueva-Meyer; Gilmer Valdes; William Chen; Julian C Hong; Sue S Yom; Timothy D Solberg; Steffen Löck; Jan Seuntjens; Catherine Park; Philippe Lambin Journal: Nat Cancer Date: 2021-07-22
Authors: Kyuwan Lee; Nathalie Sami; Debu Tripathy; Wendy Demark-Wahnefried; Mary K Norris; Kerry S Courneya; Christina M Dieli-Conwright Journal: Cardiooncology Date: 2020-11-24
Authors: Josefin Ansund; Sara Mijwel; Kate A Bolam; Renske Altena; Yvonne Wengström; Eric Rullman; Helene Rundqvist Journal: Cardiooncology Date: 2021-02-15
Authors: Dong-Woo Kang; Rebekah L Wilson; Cami N Christopher; Amber J Normann; Oscar Barnes; Jordan D Lesansee; Gyuhwan Choi; Christina M Dieli-Conwright Journal: Front Cardiovasc Med Date: 2022-01-14
Authors: E Venturini; G Iannuzzo; A D'Andrea; M Pacileo; L Tarantini; M L Canale; M Gentile; G Vitale; F M Sarullo; R Vastarella; A Di Lorenzo; C Testa; A Parlato; C Vigorito; F Giallauria Journal: J Clin Med Date: 2020-06-10 Impact factor: 4.964